CN1989126A - 新的杂环羧酸酰胺衍生物 - Google Patents

新的杂环羧酸酰胺衍生物 Download PDF

Info

Publication number
CN1989126A
CN1989126A CNA2005800241844A CN200580024184A CN1989126A CN 1989126 A CN1989126 A CN 1989126A CN A2005800241844 A CNA2005800241844 A CN A2005800241844A CN 200580024184 A CN200580024184 A CN 200580024184A CN 1989126 A CN1989126 A CN 1989126A
Authority
CN
China
Prior art keywords
formula
carboxylic acid
implication
disease
piperidines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800241844A
Other languages
English (en)
Chinese (zh)
Inventor
I·博尔扎
C·霍瓦特
S·福尔考什
I·杰尔詹
J·纳吉
S·科洛科
K·高尔戈齐
K·沙吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Vegyeszeti Gyar Nyrt
Original Assignee
Richter Gedeon Vegyeszeti Gyar RT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Vegyeszeti Gyar RT filed Critical Richter Gedeon Vegyeszeti Gyar RT
Publication of CN1989126A publication Critical patent/CN1989126A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
CNA2005800241844A 2004-07-29 2005-07-21 新的杂环羧酸酰胺衍生物 Pending CN1989126A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0401527A HU227119B1 (en) 2004-07-29 2004-07-29 Indole and benzimidazole carboxylic acid amide derivatives and pharmaceutical compositions containing them
HUP0401527 2004-07-29

Publications (1)

Publication Number Publication Date
CN1989126A true CN1989126A (zh) 2007-06-27

Family

ID=89985412

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800241844A Pending CN1989126A (zh) 2004-07-29 2005-07-21 新的杂环羧酸酰胺衍生物

Country Status (20)

Country Link
US (1) US20080300276A1 (OSRAM)
EP (1) EP1771437A1 (OSRAM)
JP (1) JP2008508251A (OSRAM)
KR (1) KR20070038503A (OSRAM)
CN (1) CN1989126A (OSRAM)
AP (1) AP2076A (OSRAM)
AU (1) AU2005266164A1 (OSRAM)
BR (1) BRPI0513900A (OSRAM)
CA (1) CA2574169A1 (OSRAM)
EA (1) EA011635B1 (OSRAM)
GE (1) GEP20084494B (OSRAM)
HU (1) HU227119B1 (OSRAM)
IL (1) IL179483A0 (OSRAM)
MA (1) MA28818B1 (OSRAM)
MX (1) MX2007001049A (OSRAM)
NO (1) NO20071112L (OSRAM)
TN (1) TNSN07014A1 (OSRAM)
UA (1) UA88643C2 (OSRAM)
WO (1) WO2006010969A1 (OSRAM)
ZA (1) ZA200700329B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2007099828A1 (ja) 2006-02-23 2009-07-16 塩野義製薬株式会社 環式基で置換された含窒素複素環誘導体
JP2013519722A (ja) 2010-02-16 2013-05-30 ファイザー・インク （ｒ）−４−（（４−（（４−（テトラヒドロフラン−３−イルオキシ）ベンゾ［ｄ］イソオキサゾール−３−イルオキシ）メチル）ピペリジン−１−イル）メチル）テトラヒドロ−２ｈ−ピラン−４−オール、５−ｈｔ４受容体の部分アゴニスト
MA40532A (fr) 2014-08-28 2021-04-28 Asceneuron Sa Inhibiteurs de glycosidases
DK3389658T3 (da) * 2015-12-18 2021-01-11 Merck Sharp & Dohme Glycosidasehæmmere og anvendelser deraf
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
MX381953B (es) 2016-02-25 2025-03-13 Asceneuron S A Sales de derivados de piperazina obtenidas por adicion de acidos.
US11612599B2 (en) 2016-02-25 2023-03-28 Asceneuron Sa Glycosidase inhibitors
US10556902B2 (en) 2016-02-25 2020-02-11 Asceneuron Sa Glycosidase inhibitors
EP3672959A1 (en) 2017-08-24 2020-07-01 Asceneuron SA Linear glycosidase inhibitors
US11731972B2 (en) 2018-08-22 2023-08-22 Asceneuron Sa Spiro compounds as glycosidase inhibitors
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
CN113166083A (zh) 2018-08-22 2021-07-23 阿森纽荣股份公司 用作糖苷酶抑制剂的哌嗪衍生物的琥珀酸盐和富马酸盐酸加成盐
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
CN113906033B (zh) 2019-06-04 2024-04-02 勃林格殷格翰国际有限公司 咪唑并吡嗪衍生物及其作为药剂的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227197B1 (en) * 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
MX2007001049A (es) 2007-04-16
WO2006010969A8 (en) 2006-08-31
WO2006010969A1 (en) 2006-02-02
NO20071112L (no) 2007-02-27
CA2574169A1 (en) 2006-02-02
AU2005266164A1 (en) 2006-02-02
EP1771437A1 (en) 2007-04-11
GEP20084494B (en) 2008-09-25
HUP0401527A3 (en) 2008-04-28
HU227119B1 (en) 2010-07-28
AP2006003843A0 (en) 2006-12-31
TNSN07014A1 (en) 2008-06-02
AP2076A (en) 2009-12-17
ZA200700329B (en) 2008-05-28
HUP0401527A2 (en) 2006-01-30
EA011635B1 (ru) 2009-04-28
US20080300276A1 (en) 2008-12-04
BRPI0513900A (pt) 2008-05-20
MA28818B1 (fr) 2007-08-01
EA200700360A1 (ru) 2007-06-29
JP2008508251A (ja) 2008-03-21
HU0401527D0 (en) 2004-09-28
IL179483A0 (en) 2007-05-15
UA88643C2 (ru) 2009-11-10
KR20070038503A (ko) 2007-04-10

Similar Documents

Publication Publication Date Title
CN100413860C (zh) 作为nmda受体拮抗剂的哌啶衍生物
EP1045693B1 (en) Aminophenoxyacetic acid derivatives as neuroprotectants
TWI299730B (en) Piperidine derivatives,processes for their preparation ,pharmaceutical composition containing them and their medical use
CN1989126A (zh) 新的杂环羧酸酰胺衍生物
JP2661699B2 (ja) ピペリジンオピオイド拮抗剤
CN1989103A (zh) 作为nmda受体拮抗剂的吲哚－2－甲脒衍生物
JP4814880B2 (ja) 新規な４−ベンジリデン−ピペリジン誘導体
CN1432009A (zh) 治疗疼痛的羟苯基－亚哌啶－4－基－甲基－苯甲酰胺衍生物
CN103068800A (zh) 作为趋化因子受体活性调节剂的哌啶基化合物
JP2006527757A (ja) 新規なピペラジニル−アリールオキシ−ｎ−アリールラクタムおよびピペラジニル−ヘテロアリールオキシ−ｎ−アリールラクタム
CN113214140B (zh) 哌啶酰胺类衍生物、其药物组合物及其应用
CN1989127A (zh) 作为nr2b受体拮抗剂的犬尿烯酸酰胺衍生物
JP7185633B2 (ja) ７員アザ複素環を含有するデルタ－オピオイド受容体調節化合物、その使用方法及び製造方法
JPWO2005079845A1 (ja) 片頭痛予防薬
KR20070039033A (ko) 신규 벤조일 우레아 유도체
Stec et al. Substituted aryl pyrimidines as potent and soluble TRPV1 antagonists
JPH07502517A (ja) 精神病の治療のためのアリールインドールの使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070627